Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adicon HoldingsHKSE:09860 +2.25%68 EV-to-FCF is 34.59 as of Aug. 29, 2026, which is 4% below its 10-year median of 36.11. GuruFocus rates HKSE:09860 with a GF Score™ of 68/100 and a GF Value™ of HK$7.24 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 104 Medical Diagnostics & Research companies, Adicon Holdings ranks worse than 59.62% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Adicon Holdings's Enterprise Value is HK$4,580 Mil.
Adicon Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$132 Mil. Therefore, Adicon Holdings's EV-to-FCF for today is 34.59.
The historical rank and industry rank for Adicon Holdings's EV-to-FCF or its related term are showing as below:
HKSE:09860'
s EV-to-FCF Range Over the Past 10 Years
Min: 10.64 Med: 36.11 Max: 61.57
Current: 33.94
During the past 6 years, the highest EV-to-FCF of Adicon Holdings was 61.57. The lowest was 10.64. And the median was 36.11.
HKSE:09860's EV-to-FCF is ranked worse than 59.62% of 104
companies
in the Medical Diagnostics & Research industry
Industry Median: 27.855
vs HKSE:09860: 33.94
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Adicon Holdings's PE Ratio (TTM) for today is calculated as:
Adicon Holdings's share price for today is HK$3.87.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Adicon Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.033.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Adicon Holdings EV-to-FCF Related Terms
Adicon Holdings EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Adicon Holdings's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:09860 vs TMO, DHR, IDXX: EV-to-FCF Comparison
For the Diagnostics & Research subindustry, Adicon Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adicon Holdings EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Adicon Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Adicon Holdings's EV-to-FCF falls into.
Adicon Holdings's current Enterprise Value is HK$4,580 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Adicon Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$132 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adicon Holdings (HKSE:09860) has a EV-to-FCF of 34.59 as of Aug. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Adicon Holdings and its competitors. This is near median its historical median of 36.11. Over the past decade, Adicon Holdings' EV-to-FCF has ranged from 10.64 to 61.57. According to the industry distribution chart, Adicon Holdings ranks #62 out of 104 companies in the Medical Diagnostics & Research industry, placing it in the top 59.6%.
Is Adicon Holdings' EV-to-FCF too high?
Adicon Holdings' current EV-to-FCF of 34.59 is near median its 10-year median of 36.11. Over the past 10 years, this metric has ranged from a low of 10.64 to a high of 61.57. The Medical Diagnostics & Research industry median EV-to-FCF is 27.86. Adicon Holdings' value of 34.59 is 24.2% above this industry median. Based on the distribution chart, Adicon Holdings ranks #62 out of 104 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Adicon Holdings has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Adicon Holdings' EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Adicon Holdings ranks #62 out of 104 companies for EV-to-FCF. This places Adicon Holdings in the lower half of its industry. The industry median EV-to-FCF is 27.86. Adicon Holdings' value of 34.59 is 24.2% above this benchmark. Historically, Adicon Holdings' own EV-to-FCF has ranged from 10.64 to 61.57 over the past decade. While the company's 10-year median is 36.11 vs. the industry median of 27.86, Adicon Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 27.86, based on 104 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adicon Holdings's current EV-to-FCF of 34.59 is 24.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Adicon Holdings and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 27.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adicon Holdings's current EV-to-FCF is 34.59, which is near median its own 10-year median of 36.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicon Holdings stock overvalued right now?
Based on GuruFocus' analysis, Adicon Holdings (HKSE:09860) is currently considered Possible Value Trap. The stock's GF Value™ is HK$7.24, compared to a current price of HK$3.87 — trading 46.5% below its estimated fair value. The current EV-to-FCF is 34.59, which is near median its 10-year median of 36.11 and 24.2% above the Medical Diagnostics & Research industry median of 27.86. Adicon Holdings' overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Adicon Holdings (HKSE:09860), the current EV-to-FCF is 34.59 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adicon Holdings (HKSE:09860) Overvalued in 2026?
Based on GuruFocus' analysis, Adicon Holdings stock appears to be undervalued.
The current stock price of HK$3.87 is trading 46.5% below its estimated GF Value™ of HK$7.24.
GuruFocus considers Adicon Holdings to be Possible Value Trap.
Key valuation signals for HKSE:09860:
EV-to-FCF: 34.59 (near median its 10-year median of 36.11)
GF Value™: HK$7.24 vs. price of HK$3.87 (46.5% below fair value)
Industry Position: 24.2% above the Medical Diagnostics & Research median (#62 of 104)
No single metric tells the full story. See the HKSE:09860 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adicon Holdings Ltd is a ICL service provider in China. It offers comprehensive testing services to hospitals and health check centers through an integrated network of self-operated laboratories across China. Its testing services platform includes clinical laboratories, pathology laboratories, reproductive genetics laboratories, gene laboratories, and mass spectrometry laboratories, consisting of over 4,000 medical diagnostic tests, the introduction of over 300 new high-end diagnostic tests.
68GF Score
Get the complete analysis for HKSE:09860
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09860 has been successfully added to your 
